MBX — MBX Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1776111 ·
Last close
$65.93
Market Cap
$3.14B
52W High
$69.40
52W Low
$28.00
ADV30
876,680
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,265,000 | -23,517,000 | 452,701,000 | 45,214,000 | 14,945,000 |
| Dec 2025 | 0 | — | -25,795,000 | -22,062,000 | 385,144,000 | 75,289,000 | 15,921,000 |
| Sep 2025 | 0 | — | -23,926,000 | -21,618,000 | 400,076,000 | 223,125,000 | 12,538,000 |
| Jun 2025 | 0 | — | -21,805,000 | -19,411,000 | 231,522,000 | 39,781,000 | 12,283,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-79,949,000
Investing CF
$-83,705,000
Financing CF
$189,592,000
CapEx
$-1,929,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-224,476,000
Inventory
—
Receivables
$2,120,000
ST Investments
$298,416,000
EBIT TTM
$-98,055,000
Pretax Income TTM
$-86,971,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -98,055,000 | -86,971,000 | 385,144,000 | 15,921,000 | — | -79,949,000 |
| Dec 2024 | 0 | -68,194,000 | -61,922,000 | 268,535,000 | 11,093,000 | — | -54,681,000 |
| Dec 2023 | 0 | -35,311,000 | -32,563,000 | 84,180,000 | 156,648,000 | — | -31,978,000 |
| Dec 2022 | 0 | -25,161,000 | -26,135,000 | 45,095,000 | 87,700,000 | — | -23,122,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.62
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $65.93 · call volume: 108 · put volume: 4
Expected Move to 2026-12-18:
±$33.05
(50.13%) —
implied range
$32.88 –
$98.98
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $3.25B | $27.79 | — |
| QURE | uniQure N.V. | $3.03B | $43.63 | — |
| IRON | Disc Medicine, Inc. | $2.96B | $77.00 | — |
| TLPPF | Telix Pharmaceuticals Ltd | $3.34B | $9.86 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.35B | $9.89 | — |
News headlines (Yahoo Finance, 1h cache)
Stock Market Checklist Helps Uncover Winners In Hot Biotechs
2026-07-31 15:09 · Yahoo
Attovia Therapeutics Appoints John W. Smither to Board of Directors
2026-07-15 12:30 · Yahoo
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
2026-07-13 20:15 · Yahoo
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhib
2026-07-07 14:31 · Yahoo
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
2026-06-15 20:14 · Yahoo
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
2026-06-12 12:52 · Yahoo
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
2026-06-12 11:00 · Yahoo
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
2026-06-11 09:27 · Yahoo
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
2026-06-01 12:00 · Yahoo
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
2026-05-27 19:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.